SS-31
Approved for Barth syndrome; Broader mitochondrial uses remain investigational
Brief Overview: SS-31, now approved as elamipretide under the FORZINITY label, targets cardiolipin in the inner mitochondrial membrane. The approved use is narrow. Evidence lens: Approval scope matters. Evidence supporting accelerated approval for Barth syndrome does not prove general fatigue, longevity, or mitochondrial optimization use in healthy people. How to read this: if you're new, read the indication, patient weight threshold, route, and label warnings. Once you're past the basics, separate disease-specific endpoints, confirmatory-trial obligations, and off-label speculation.
- SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide.
- The approved commercial product is FORZINITY for Barth syndrome; Research-grade SS-31 is not automatically interchangeable with the approved drug product.
- SS-31/elamipretide is a mitochondria-targeted tetrapeptide that binds cardiolipin-associated mitochondrial membranes. Approved Forzinity is a specific elamipretide product for Barth syndrome, not a general mitochondrial wellness peptide.
- Elamipretide binds cardiolipin and is intended to stabilize inner mitochondrial membrane function, support electron-transport efficiency, and reduce mitochondrial oxidative stress in the disease context studied.
- The mechanism centers on mitochondrial inner-membrane/cardiolipin stabilization and improved electron transport efficiency under stress. It does not simply increase energy for everyone. The mechanism here is a plausibility map, not proof of a clinical outcome.
- The approved Barth syndrome indication is based on an intermediate endpoint involving muscle strength and remains subject to confirmatory-trial requirements.
- Other disease programs and wellness uses are separate and do not generalize.
- Elamipretide has disease-specific trial and regulatory evidence, culminating in accelerated approval for Barth syndrome. Evidence for broad fatigue, aging, or athletic use remains separate and unproven. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Clinical (FDA/Barth) Protocol [FDA/Approved/Label]; Route: Subcutaneous (SC); Dose: 40 mg (Fixed SC dose); Frequency: Once daily; Duration: Chronic (for Barth Syndrome); Status: Yes - FDA-approved label/product protocol for the labeled indication only.
- Protocol 2: Common Research/Biohacker [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or IV Infusion; Dose: 10 mg – 40 mg; Frequency: Once daily; Duration: 4 to 8 weeks; Max: IV Dose: 0.05 mg/kg/h (Slow infusion); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: FORZINITY FDA-label Barth syndrome protocol [FDA/Approved/Label]; Route: Subcutaneous injection; Dose: 40 mg; Frequency: Once daily; Timing: Same time each day; Duration: Chronic labeled use; Accelerated approval context; Status: Yes - FDA-approved label/product protocol for Barth syndrome in patients weighing at least 30 kg only.
- Forzinity label dosing is separate from research-market SS-31 dosing reports. Approved product instructions, missed-dose rules, and no-mix instructions override general peptide logic. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: Per label language – minimal accumulation with daily dosing.
- Half-life basis: the FORZINITY label gives daily subcutaneous PK with minimal accumulation but does not present a simple half-life-based steady-state estimate suitable for general extrapolation.
- Beginner translation: If you're new, this means do not force a generic half-life rule when the label frames the product differently.
- Practical interpretation: For approved Barth syndrome use, follow the label and specialist care. Do not extrapolate PK to general mitochondrial optimization.
- Daily SC product context is relevant for Forzinity, but research formulations may not match. Mitochondrial targeting and tissue disease context matter more than a generic half-life. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- MOTS-c, NAD+, coenzyme Q10, exercise, or photobiomodulation pairings are mechanistic or anecdotal unless tested for the same indication. Mitochondrial stacks should not be portrayed as label-supported.
- Often discussed with MOTS-c, Humanin, NAD, CoQ10, or exercise/mitochondrial stacks. Avoid same-syringe mixing because the approved label specifically says not to mix Forzinity with other medicines in the same syringe. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Use the current FORZINITY label for adverse reactions, warnings, and monitoring in approved use.
- Research-grade SS-31 has separate quality, sterility, and regulatory risks.
- Injection reactions, hypersensitivity, disease-specific monitoring, and unknown off-label long-term use are key. Approved status for Barth syndrome does not generalize safety to healthy users. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- In approved disease use, monitoring is disease-specific and clinician-directed.
- General ATP tests or wellness mitochondrial panels are not validated endpoints for broad use.
- Track functional capacity, fatigue, muscle symptoms, injection reactions, and disease-specific markers when used clinically. In research contexts, objective exercise tolerance measures are more useful than vague energy ratings. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: accelerated approval for FORZINITY in Barth syndrome patients weighing at least 30 kg.
- Not approved for general mitochondrial optimization.
- Other jurisdictions require current-status verification.
- Forzinity/elamipretide is FDA accelerated-approved for Barth syndrome in patients weighing at least 30 kg. SS-31 research products are not automatically equivalent to the approved drug. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.